Plain-English translation of NCT07325097 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing PVEK, a tissue-engineered implant designed to replace a damaged layer of cells in the cornea (the clear front part of the eye). The implant is being studied in people with corneal swelling caused by Fuchs' endothelial dystrophy or complications from cataract surgery. This is an early-stage study to learn whether the treatment is safe and whether it helps restore vision.
Corneal swelling from certain eye diseases or previous surgeries can cause blurred vision and discomfort, and current treatments don't work for everyone. This trial is exploring whether a laboratory-grown implant can repair the damaged cell layer and restore clearer vision without needing a donor cornea transplant.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will have screening tests including eye exams and health checks, then receive surgery to implant the corneal tissue. After surgery, you will use prescribed eye drops and return for follow-up visits over 12 months, where doctors will perform vision tests, check eye pressure, and use imaging scans to monitor how the implant is working.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
Armenia
Israel